Cradling life through
precision therapeutics
PretermX is developing the first uterus-targeted therapeutics to prevent preterm birth by building a new category of precision medicine for one of the most significant unmet needs in women's health
THE CHALLENGE
A safe, durable way to stop preterm labor.
PROBLEM
Systemic, off-label, dose-limited
Current treatments are systemic, off-label,
and dose-limited by side effects that result in
insufficient duration of use, leaving clinicians without a safe, durable way to stop preterm labor.
SOLUTION
Delivered to the source
Novel small-molecule and antibody-drug
conjugate platforms engineered to deliver
clinically validated payloads directly to the uterus and suppress contractions at the source.
PROGRESS
PTX-101 validated
Our lead program has demonstrated
suppression of uterine contractions in human tissue and delay of preterm birth in preclinical models while improving neonatal outcomes.
LEAD PROGRAM
PTX-101 has demonstrated suppression of uterine contractions in human tissue and delay of preterm birth in preclinical models while improving neonatal outcomes.
PTX-101
Leadership
CO-FOUNDER
Dr. Herington is a reproductive biologist
focused on uterine physiology and the
molecular drivers of preterm labor
Jennifer Herington, PhD
Todd D. Giorgio, PhD
CO-FOUNDER
Dr. Giorgio is a biomedical engineer
pioneering targeted drug delivery and translational nanotherapeutics
Advance neonatal health with us.
For inquiries on partnerships, investment, or clinical collaboration. We would love to hear from you.